IDEXX LABORATORIES INC
NASDAQ: IDXX (IDEXX Laboratories, Inc.)
Last update: 1 hour ago509.42
0.29 (0.06%)
| Previous Close | 509.13 |
| Open | 507.00 |
| Volume | 552,498 |
| Avg. Volume (3M) | 880,260 |
| Market Cap | 40,968,527,872 |
| Price / Earnings (TTM) | 47.17 |
| Price / Earnings (Forward) | 36.76 |
| Price / Sales | 9.33 |
| Price / Book | 22.20 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2025 - 8 Aug 2025 |
| Profit Margin | 22.78% |
| Operating Margin (TTM) | 27.42% |
| Diluted EPS (TTM) | 10.66 |
| Quarterly Revenue Growth (YOY) | 5.80% |
| Quarterly Earnings Growth (YOY) | 11.10% |
| Total Debt/Equity (MRQ) | 61.87% |
| Current Ratio (MRQ) | 1.31 |
| Operating Cash Flow (TTM) | 929.00 M |
| Levered Free Cash Flow (TTM) | 734.99 M |
| Return on Assets (TTM) | 22.69% |
| Return on Equity (TTM) | 57.66% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bearish | Bearish |
| Diagnostics & Research (Global) | Bearish | Bearish | |
| Stock | IDEXX Laboratories, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -3.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.0 |
| Average | -0.75 |
|
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.67% |
| % Held by Institutions | 94.28% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Fundsmith Llp | 31 Dec 2024 | 2,662,855 |
| Bamco Inc /Ny/ | 31 Dec 2024 | 2,005,522 |
| Price T Rowe Associates Inc /Md/ | 31 Mar 2025 | 1,988,912 |
| Alliancebernstein L.P. | 31 Dec 2024 | 1,239,220 |
| Principal Financial Group Inc | 31 Mar 2025 | 1,126,002 |
| Blair William & Co/Il | 31 Mar 2025 | 1,090,770 |
| Norges Bank | 31 Dec 2024 | 997,140 |
| Northern Trust Corp | 31 Mar 2025 | 905,067 |
| American Century Companies Inc | 31 Mar 2025 | 867,992 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 558.00 (Morgan Stanley, 9.54%) | Buy |
| Median | 489.00 (-4.01%) | |
| Low | 420.00 (Stifel, -17.55%) | Hold |
| Average | 489.00 (-4.01%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 439.86 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 05 May 2025 | 558.00 (9.54%) | Buy | 475.07 |
| Stifel | 14 Apr 2025 | 420.00 (-17.55%) | Hold | 404.65 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ESSIG STUART | - | - | 0 | 0 |
| JUNIUS DANIEL M | - | - | 0 | 0 |
| KINGSLEY LAWRENCE D | - | - | 0 | 0 |
| SZOSTAK M ANNE | - | - | 0 | 0 |
| VANDEBROEK SOPHIE V. | - | - | 0 | 0 |
| Aggregate Net Quantity | 0 | |||
| Aggregate Net Value ($) | 0 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ESSIG STUART | Director | 06 May 2025 | Option execute | 262 | - | - |
| JUNIUS DANIEL M | Director | 06 May 2025 | Option execute | 262 | - | - |
| KINGSLEY LAWRENCE D | Director | 06 May 2025 | Option execute | 346 | - | - |
| SZOSTAK M ANNE | Director | 06 May 2025 | Option execute | 262 | - | - |
| VANDEBROEK SOPHIE V. | Director | 06 May 2025 | Option execute | 262 | - | - |
| Date | Type | Details |
|---|---|---|
| 13 May 2025 | Announcement | IDEXX Laboratories to Present at Stifel Conference and Announces 2025 Investor Day |
| 01 May 2025 | Announcement | IDEXX Laboratories Announces First Quarter Results |
| 03 Apr 2025 | Announcement | IDEXX Laboratories to Release 2025 First Quarter Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |